Condition: Obesity & Overweight · Sponsor: Corxel Pharmaceuticals
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
This description comes directly from the study's public registry record.
Study coordinator · 201-268-3723 · information.center@corxelbio.com
Always discuss trial participation with your own doctor first.
| Corxel Investigational site | Las Vegas, Nevada, United States | Recruiting |
| Corxel Investigational Site | Austin, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07652047